EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY
Equipe constitutive du CERPOP, UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier
Lise CUZIN •  chercheur


  1. Bachelard A, Isernia V, Charpentier C, Benalycherif A, Mora M, Donadille C, Duvivier C, Lacombe K, El Mouhebb M, Spire B, Landman R, Descamps D, Peytavin G, Assoumou L, Ghosn J; FAST study group (Cuzin L colloborator). Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055. J Antimicrob Chemother. 2023 Mar 2;78(3):769-778. doi: 10.1093/jac/dkad008.
  2. Cabras O, Sylvanise L, Marquise A, Cabié A, Cuzin L. Knowledge on human papillomavirus (HPV), HPV screening and HPV vaccine among sexual health clinic patients in Martinique, French West Indies. Infect Dis Now. 2023 Mar;53(2):104634. doi: 10.1016/j.idnow.2022.11.003.
  3. Cuzin L, Flandre P, Allavena C, Palich R, Duvivier C, Becker A, Laroche H, Pugliese P, Cabie A; Dat’AIDS Study Group. Low-level viral loads and virological failure in the integrase strand transfer era. J Antimicrob Chemother. 2023 Apr 3;78(4):1111-1116. doi: 10.1093/jac/dkad056.
  4. Cuzin L, Morisot A, Allavena C, Lert F, Pugliese P; Dat’AIDS Study Group. Drastic reduction in time to controlled viral load in people with HIV in France (2009-2019): a longitudinal cohort study. Clin Infect Dis. 2023 Sep 4:ciad530. doi: 10.1093/cid/ciad530. Epub ahead of print.
  5. Palich R, Hentzien M, Hocqueloux L, Duvivier C, Allavena C, Huleux T, Delobel P, Makinson A, Rey D, Cuzin L; Dat'AIDS Study Group. Country of birth is associated with antiretroviral therapy choice in treatment-naive persons living with HIV in France. AIDS. 2023 Apr 21. doi: 10.1097/QAD.0000000000003588.
  6. Palich R, Agher R, Wetshikoy DJ, Cuzin L, Seang S, Soulie C, Tubiana R, Valantin MA, Schneider L, Pourcher V, Marcelin AG, Assoumou L, Katlama C. Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):144-152. doi: 10.1097/QAI.0000000000003114.

  1. Cabras O, Turmel JM, Rami A, Cuzin L. Correspondence on 'Pulmonary endocarditis due to Neisseria gonorrhoeae in a patient living with HIV' by Cabras et al. Sex Transm Infect. 2022 May 6:sextrans-2022-055428. doi: 10.1136/sextrans-2022-055428. Epub ahead of print.
  2. Cabras O, Turmel JM, Olive C, Bigeard B, Lehoux M, Pierre-Francois S, Guitteaud K, Abel S, Cuzin L, Cabié A. COVID-19 and Pasteurella multocida Pulmonary Coinfection: A Case Series. Trop Med Infect Dis. 2022 Dec 11;7(12):429. doi: 10.3390/tropicalmed7120429.
  3. Cuzin L, Cabras O, Marquise A, Pierre-François S, Pircher M, Cabié A; CHUM HIV prevention study group. Challenges of providing HIV pre-exposure prophylaxis in Martinique, French West Indies. Sex Transm Infect. 2022 Aug;98(5):387. doi: 10.1136/sextrans-2021-055158.
  4. Cuzin L, Delobel P, Martin-Blondel G. Letter to the editor. HIV Med. 2022 Feb;23(2):204-205. doi: 10.1111/hiv.13192.
  5. Demeulemeester R, Savy N, Mounié M, Molinier L, Delpierre C, Dellamonica P, Allavena C, Pugliesse P, Cuzin L, Saint-Pierre P, Costa N. Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023. BMC Health Serv Res. 2022 Apr 27;22(1):567. doi: 10.1186/s12913-022-07859-w.
  6. Lajaunie R, Cuzin L, Palich R, Makinson A, Bani-Sadr F, Duvivier C, Arvieux C, Rey D, Poizot-Martin I, Delpierre C, Delobel P, Martin-Blondel G; And The Dat’AIDS study group. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy. HIV Med. 2022 Mar;23(3):301-306. doi: 10.1111/hiv.13168.
  7. Palich R, Teyssou E, Sayon S, Abdi B, Soulie C, Cuzin , Tubiana R, Valantin MA, Schneider L, Seang S, Wirden M, Pourcher V, Katlama C, Calvez V, Marcelin AG. Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients. J Infect Dis. 2022 Feb 1;225(3):502-509. doi: 10.1093/infdis/jiab413.
  8. Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration  (Cuzin L collaborator). A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688.
  1. Cuzin L, Allavena C, Cotte L, Delpierre C, Huleux T, Palich R, Delobel P, Raffi F, Cabié A; Dat’AIDS Study Group. No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study. J Antimicrob Chemother. 2021 May 12;76(6):1573-1579. . doi: 10.1093/jac/dkab061.
  2. Deschanvres C, Reynes J, Lamaury I, Rey D, Palich R, Bani-Sadr F, Robineau O, Duvivier C, Hocqueloux L, Cuzin L, Joly V, Raffi F, Cabie A, Allavena C; Dat’AIDS Study Group. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. J Antimicrob Chemother. 2021 Dec 24;77(1):196-204. doi: 10.1093/jac/dkab367.
  1. Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, APROCO-COPILOTE ANRS CO8 Study Group (Cuzin L collaborator). Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020;36(5):399‐405. doi:10.1089/AID.2019.0229.
  2. Hentzien M, Cuzin L, Raffi F, Jacomet C, Reynes J, Rey D, Ravaux I, Cheret A, Viguier M, Bani-Sadr F , Dat’AIDS study group. Factors associated with psoriasis in a French Nationwide HIV cohort: the independent role of HLA-B*57:01. AIDS. 2020;34(7):1057‐1063.doi:10.1097/QAD.0000000000002519.
  3. Le Guillou A, Pugliese P, Raffi F, Cabie A, Cuzin L, Katlama C, Allavena C, Drame M, Cotte L, Bani-Sadr F; Dat’AIDS Study Group. Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort. Clin Infect Dis. 2020 Jul 11;71(2):293-300. doi: 10.1093/cid/ciz800.
  4. Pircher M, Pitono E, Pierre-François S, Molcard S, Brunier-Agot L, Fagour L, Najioullah F, Cesaire R, Abel S, Cuzin L, Cabié A. The effects of chikungunya virus infection on people living with HIV during the 2014 Martinique outbreak. PLoS One. 2020;15(6):e0234267.  doi:10.1371/journal.pone.0234267.
  5. Poizot-Martin I, Obry-Roguet V, Duvivier C, Lions C, Huleux T, Jacomet C, Ferry T, Cheret A, Allavena C , Bani-Sadr F, Palich R, Cabié A , Fresard A, Pugliese P, Delobel  P, Lamaury I, Hustache-Mathieu L, Brégigeon S, Makinson  A , Rey D, Dat'AIDS study group (Cuzin L collaborator). Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015. J Eur Acad Dermatol Venereol. 2020;34(5):1065‐1073. doi:10.1111/jdv.16204.
  6. Ursenbach A, Max V, Maurel M, Bani-Sadr F, Gagneux-Brunon A, Garraffo R, Ravaux I, Robineau O, Makinson A, Rey D; Dat’AIDS Study Group (Cuzin L collaborator). Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. J Antimicrob Chemother. 2020 Nov 1;75(11):3344-3348. doi: 10.1093/jac/dkaa330.
  1. Cuzin L, Cotte L, Delpierre C, Allavena C, Valantin MA, Rey D, Delobel P, Pugliese P, Raffi F, Cabié A; Dat’AIDS Study group. Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort. PLoS One. 2019 Sep 6;14(9):e0222067. doi: 10.1371/journal.pone.0222067.
  2. Cuzin L, Pugliese P, Katlama C, Bani-Sadr F, Ferry T, Rey D, Lourenco J, Bregigeon S, Allavena C, Reynes J, Cabié A; Dat’AIDS Study Group. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. J Antimicrob Chemother. 2019 Mar 1;74(3):754-760. doi: 10.1093/jac/dky497.
  3. Durier C , Desaint C , Lelièvre JD , Silbermann B, Pialoux G, Cuzin L , Bonnet B, Poizot-Martin I, Bouakane A, Paul C, Grabar S , Spire B , Meyer L , Launay O, ANRS/VRI COHVAC Study Group Long-term Safety and Vaccine-Induced Seropositivity in Healthy Volunteers From HIV Vaccine Trials. AIDS. 2019. 33 (13), 2061-2071. doi: 10.1097/QAD.0000000000002310.
  4. Hentzien M, Dramé M, Delpierre C, Allavena C, Cabié A, Cuzin L, Rey D, Pugliese P, Hédelin G, Bani-Sadr F; Dat’AIDS Study Group. HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat'AIDS cohort. BMJ Open. 2019 Jan 25;9(1):e024841. doi: 10.1136/bmjopen-2018-024841.
  5. Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, Cabié A, Bonnet B, Duvivier C, Hocqueloux L, Cua E, Cheret A, Hustache-Mathieu L, Obry-Roguet V, Jacomet C, Poizot-Martin I; DAT’AIDS STUDY GROUP. (Cuzin L. collaborator) Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort. BMC Infect Dis. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5.
  6. Pugliese P, Joly V, Valantin MA, Cotte L, Huleux T, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Cuzin L; Dat’AIDS group. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France. Med Mal Infect. 2019 Jun;49(4):264-269. doi: 10.1016/j.medmal.2018.10.005.
  7. Sagaon-Teyssier L, Vilotitch A, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, Dray-Spira R, Spire B; VESPA2 study group.  (Cuzin L. collaborator) A generalized additive model to disentangle age and diagnosis-specific cohort effects in psychological and behavioral outcomes in people living with HIV: the French cross-sectional ANRS-VESPA2 survey. BMC Public Health. 2019 May 17;19(1):590. doi: 10.1186/s12889-019-6905-z.